PIK3CA assay guides treatment of progressing breast cancer: Katherine Geiersbach, M.D.
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32)
Could you provide a little bit of background about yourself, please?
(01:01)
Please give us a brief overview of the new PIK3CA assay.
(02:09)
Why do we offer two different tests, and when should each be ordered?
(03:58)
Which patients should have this testing?
(04:39)
Is this testing used for patients being considered for second-line treatment after first-line hormone receptor treatment?
(05:20)
Is there anything else you would like to add about the PIK3CA testing?
(06:23)
Why is it important to know the molecular signature of these tumors?